印度制药公司预测25财政年度收入增长9-1%,前景稳定,营业利润稳定。 Indian pharma companies forecast 9-11% revenue growth in FY25, with stable outlook and steady operating margins.

预计印度制药公司在25财政年度将实现收入增长9-9%,低于24财政年度的13-14%。 Indian pharmaceutical companies are anticipated to achieve 9-11% revenue growth in FY25, down from 13-14% in FY24. 预计主要市场将实现增长:9-11%来自美国,7-9%来自欧洲和国内,11-13%来自新兴市场。 Growth is expected from key markets: 9-11% from the US, 7-9% from Europe and domestically, and 11-13% from emerging markets. 协会以需求强劲和信用状况强劲为由,保持了该部门的稳定前景。 ICRA maintains a stable outlook for the sector, citing strong demand and robust credit profiles. 预计业务利润率将稳定在23-24%,并辅以复杂的非专利商品的增加和有利的原材料成本。 Operating margins are projected to remain steady at 23-24%, supported by increases in complex generics and favorable raw material costs.